Trevena, Inc.

285 articles about Trevena, Inc.

• Trevena Awarded OLINVYK Agreement with Premier, Inc.

  12/4/2023

  Trevena Inc. has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc. Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OLINVYK.

• Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

  12/4/2023

  Trevena, Inc. today announced a poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology (ACNP). The conference is being held from December 3rd to 6th, 2023.

• Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

  11/30/2023

  Trevena, Inc. announced the acceptance of an abstract based on the pRospective, case-controlled Evaluation of oLIceridine for moderate or sEVEre pain in patients with acute burn injuries study at the 2024 ABA annual meeting, being held April 9th-12th in Chicago.

• Trevena Reports Third Quarter 2023 Results and Provides Business Update

  11/14/2023

  Trevena, Inc. reported its financial results for the third quarter ended September 30, 2023 and provided an overview of its recent operational highlights.

• Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

  11/9/2023

  Trevena, Inc. announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023.

• Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

  10/16/2023

  Trevena, Inc. (Nasdaq: TRVN) today reported topline safety and tolerability data for the two Phase 1 proof-of-concept (POC) studies of TRV045, a novel sphingosine-1 phosphate receptor modulator selective for the S1P receptor subtype 1.   

• Trevena Reports Second Quarter 2023 Results and Provides Business Update

  8/14/2023

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter ended June 30, 2023 and provided an overview of its recent operational highlights.

• Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

  7/20/2023

  Trevena, Inc. announced that Mark Corrigan, M.D. has been appointed to the Company’s Board of Directors, effective July 18 2023.

• Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study

  6/26/2023

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced new topline OLINVYK data from the ARTEMIS study.

• Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical

  5/31/2023

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of OLINVYK.

• Trevena Reports First Quarter 2023 Results and Provides Business Update

  5/15/2023

  Trevena, Inc. reported its financial results for the first quarter ended March 31, 2023, and provided an overview of its recent operational highlights.

• Trevena to Release First Quarter 2023 Financial Results on May 15, 2023

  5/9/2023

  Trevena, Inc. announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023.

• Trevena Announces Approval of OLINVYK in China

  5/8/2023

  Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that its partner in China, Jiangsu Nhwa, received formal approval from the National Medical Products Administration for OLINVYK.

• Trevena to Participate in Three Upcoming Conferences

  5/3/2023

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that members of Management will participate in three upcoming conferences.

• Trevena Reports Fourth Quarter 2022 Results and Provides Business Update

  3/30/2023

  Trevena, Inc. reported its financial results for the fourth quarter ended December 31, 2022 and provided an overview of its recent operational highlights.

• Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study

  3/30/2023

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced initial topline OLINVYK data from two related real-world outcomes studies: VOLITION and ARTEMIS.

• Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023Company to host a Conference Call & Webcast at 8:00 a.m. ET

  3/27/2023

  Trevena, Inc. today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, prior to the market open on Thursday, March 30, 2023.

• Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders

  3/7/2023

  Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1.

• Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY

  2/14/2023

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of OLINVYK data in the peer-reviewed journal Anesthesiology.

• Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

  1/9/2023

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the enrollment of the first subject in a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1.